Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joinn Laboratories (China) Co's quarterly other current assets
declined
from Sep. 2025 (¥997 Mil) to Dec. 2025 (¥881 Mil) and
declined
from Dec. 2025 (¥881 Mil) to Mar. 2026 (¥690Mil).
Joinn Laboratories (China) Co's annual other current assets
declined
from Dec. 2023 (¥1,671 Mil) to Dec. 2024 (¥843 Mil)
increased
from Dec. 2024 (¥843 Mil) to Dec. 2025 (¥881 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co Other Current Assets Chart
Joinn Laboratories (China) Co Other Current Assets Calculation
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
Cash
Trade Receivables
Inventory
The assets grouped under other current assets are most commonly:
Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
What does a Other Current Assets of ¥690 Mil mean?
Joinn Laboratories (China) Co (SHSE:603127) has a Other Current Assets of ¥690 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Joinn Laboratories (China) Co.
Is Joinn Laboratories (China) Co's Other Current Assets too high?
Joinn Laboratories (China) Co's current Other Current Assets is ¥690 Mil. Overall, Joinn Laboratories (China) Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Other Current Assets compare to TMO and DHR?
Joinn Laboratories (China) Co's Other Current Assets of ¥690 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Medical Diagnostics & Research company?
A good Other Current Assets depends on the Medical Diagnostics & Research industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Joinn Laboratories (China) Co. Joinn Laboratories (China) Co's current Other Current Assets is ¥690 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.67, compared to a current price of ¥46.46 — trading 162.9% above its estimated fair value. The current Other Current Assets is ¥690 Mil. Joinn Laboratories (China) Co's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Other Current Assets is ¥690 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥46.46 is trading 162.9% above its estimated GF Value™ of ¥17.67.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
Other Current Assets: ¥690 Mil
GF Value™: ¥17.67 vs. price of ¥46.46 (162.9% above fair value)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
71GF Score
Get the complete analysis for SHSE:603127
Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
